Needham lowered the firm’s price target on Boston Scientific (BSX) to $97 from $121 and keeps a Buy rating on the shares. The company’s organic growth slowed to 12.7% in Q4 from 15.3% in Q3 as FARAPULSE growth slowed due to increasing competition and slowing PFA adoption, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target lowered to $105 from $120 at BofA
- Boston Scientific price target lowered to $115 from $140 at Mizuho
- Boston Scientific price target lowered to $96 from $112 at Evercore ISI
- Boston Scientific price target lowered to $110 from $125 at Stifel
- Boston Scientific price target lowered to $100 from $135 at JPMorgan